<DOC>
	<DOCNO>NCT00250562</DOCNO>
	<brief_summary>Valsartan , orally active angiotensin II receptor blocker , register country worldwide treatment hypertension . In China usual recommend start maintenance dose 80 mg o.d . The combination HCTZ 12.5 mg valsartan 80 mg show additive effect lower blood pressure compare valsartan 80 mg patient adequately control valsartan 80 mg monotherapy5 non-selected patients6 . This fixed combination register country worldwide . The potential benefit combination evaluate patient adequately control valsartan 80 mg monotherapy . This study compare efficacy , safety tolerability add HCTZ 12.5 mg valsartan 80 mg hypertensive patient . This study recruit US .</brief_summary>
	<brief_title>A Study Chinese Mild Moderate Hypertensive Patients Comparing Efficacy Co-Diovan With Diovan .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female Outpatients 18 year old . Patients hypertension define follow : Newly diagnose hypertensive patient MSDBP &gt; 95 mmHg &lt; 110 mmHg.at Visit 1 2 , Pretreated hypertensive patient MSDBP &gt; 95 mmHg &lt; 110 mmHg Visit 2 For entrance doubleblind treatment period ( Visit 3 ) , patient MSDBP &gt; 90 mmHg &lt; 110 mmHg Patients must give write informed consent participate willing participate entire study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin II receptor blocker</keyword>
	<keyword>fix combination</keyword>
	<keyword>diuretic</keyword>
</DOC>